Powder: -20°C for 3 years | In solvent: -80°C for 1 year
EC5026 (BPN-19186) has the potential to relieve pain by stabilizing natural analgesic and anti-inflammatory mediators.
説明 | EC5026 (BPN-19186) has the potential to relieve pain by stabilizing natural analgesic and anti-inflammatory mediators. |
In vivo | EC5026 (BPN-19186) is a first-in-class, small molecule that potently inhibits soluble Epoxide Hydrolase (sEH), a key regulatory enzyme involved in the metabolism of membrane fatty acids.?Inhibition of sEH treats pain by stabilizing natural analgesic and anti-inflammatory mediators.?sEH inhibitors developed by EicOsis have already shown efficacy for treating pain with no apparent adverse or addictive effects in laboratory animals and relieving naturally occurring pain in dogs, cats and horses. |
別名 | BPN-19186 |
分子量 | 405.39 |
分子式 | C18H23F4N3O3 |
CAS No. | 1809885-32-2 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 250 mg/mL (616.69 mM)
You can also refer to dose conversion for different animals. 詳細
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
EC5026 1809885-32-2 Metabolism Epoxide Hydrolase sEH analgesic BPN 19186 pain inhibit Hydrolase anti-inflammatory Inhibitor mediators Epoxide EC 5026 BPN19186 EC-5026 BPN-19186 Soluble inhibitor